A Comparison of the Efficacy and Safety of Quinapril with that of Enalapril in the Treatment of Mild to Moderate Essential Hypertension
Keyword(s):
This twenty-eight-week double- blind study in patients with mild to moderate essential hypertension showed quinapril (10, 20, and 40 mg/ day) to be similarly effective to enal april at the same doses in producing clinically significant reductions in sit ting DBP. Hydrochlorothiazide could be safely added to quinapril therapy in nonresponders. Quinapril and enalapril were well tolerated. Both agents can safely be administered as first-line therapy.
195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)
